Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MDT
stocks logo

MDT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
8.89B
+7.23%
1.337
-3.82%
9.63B
+7.91%
1.686
+4.06%
9.05B
+6.02%
1.373
+8.94%
Estimates Revision
The market is revising Upward the revenue expectations for Medtronic plc (MDT) for FY2026, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by 9.84%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.09%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-0.02%
In Past 3 Month
Stock Price
Go Up
up Image
+9.84%
In Past 3 Month
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
11 Hold
0 Sell
Moderate Buy
Current: 101.990
sliders
Low
90.00
Averages
110.47
High
119.00
Current: 101.990
sliders
Low
90.00
Averages
110.47
High
119.00
Barclays
NULL -> Overweight
maintain
$109 -> $111
2025-11-20
Reason
Barclays
Price Target
$109 -> $111
2025-11-20
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Medtronic to $111 from $109 and keeps an Overweight rating on the shares. The firm upped estimates following the company's organic growth "beat and raise" quarter.
Wells Fargo
Overweight
maintain
$100 -> $114
2025-11-19
Reason
Wells Fargo
Price Target
$100 -> $114
2025-11-19
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Medtronic to $114 from $100 and keeps an Overweight rating on the shares. The firm notes Q2 organic growth of 5.5% exceeded Street, while EPS beat even with the increased opex spend. Medtronic continues to expect a top-line acceleration into the second half of the year and beyond, Wells adds.
Baird
David Rescott
Neutral
maintain
$103 -> $109
2025-11-19
Reason
Baird
David Rescott
Price Target
$103 -> $109
2025-11-19
maintain
Neutral
Reason
Baird analyst David Rescott raised the firm's price target on Medtronic to $109 from $103 and keeps a Neutral rating on the shares. The firm updated its model as its investment in growth adds to the story but OM expansion continues to lag.
UBS
Neutral
maintain
$95 -> $102
2025-11-19
Reason
UBS
Price Target
$95 -> $102
2025-11-19
maintain
Neutral
Reason
UBS raised the firm's price target on Medtronic to $102 from $95 and keeps a Neutral rating on the shares. Execution remains key for reacclerating organic sales growth, the analyst tells investors in a research note.
Bernstein
Lee Hambright
Outperform
maintain
$98 -> $111
2025-11-19
Reason
Bernstein
Lee Hambright
Price Target
$98 -> $111
2025-11-19
maintain
Outperform
Reason
Bernstein analyst Lee Hambright raised the firm's price target on Medtronic to $111 from $98 and keeps an Outperform rating on the shares. The firm notes the company delivered better than expected performance on both sales and adjusted EPS. Management is committed to ensuring investment in growth drivers and delivering earnings leverage, Bernstein adds.
Citi
Joanne Wuensch
Buy
maintain
$112 -> $117
2025-11-18
Reason
Citi
Joanne Wuensch
Price Target
$112 -> $117
2025-11-18
maintain
Buy
Reason
Citi analyst Joanne Wuensch raised the firm's price target on Medtronic to $117 from $112 and keeps a Buy rating on the shares. The company reported better revenue growth in fiscal Q2 and it highlighted "generational growth drivers" going forward, the analyst tells investors in a research note. Citi says medical technology valuations tend to follow sales growth and that Medtronic's growth is picking up in the second half of its fiscal year.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Medtronic PLC (MDT.N) is 17.41, compared to its 5-year average forward P/E of 17.16. For a more detailed relative valuation and DCF analysis to assess Medtronic PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
17.16
Current PE
17.41
Overvalued PE
19.77
Undervalued PE
14.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.51
Undervalued EV/EBITDA
12.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.81
Current PS
0.00
Overvalued PS
4.55
Undervalued PS
3.07
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 288.1% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 167.88% over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased100%over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 288.1% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MDT News & Events

Events Timeline

(ET)
2025-12-03
16:40:00
Medtronic's Hugo Robotic Surgery System Cleared by FDA
select
2025-12-02 (ET)
2025-12-02
09:11:00
Medtronic Launches MiniMed 780G System, Marking Major Milestone in Diabetes Management
select
2025-11-18 (ET)
2025-11-18
09:55:01
Significant Early Gainers in Liquid Options on November 18th
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedFDA Approves Medtronic's Hugo Robotic Surgery System for Urological Use

  • FDA Clearance for Hugo RAS System: Medtronic has received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, enhancing its surgical innovation portfolio.

  • Expansion in Robotic Surgery Market: The modular design and integration with the Touch Surgery digital ecosystem position Medtronic to expand its presence in the growing robotic surgery market.

  • Support for Minimally Invasive Care: The clearance supports the adoption of minimally invasive care and strengthens Medtronic's long-term growth opportunities in healthcare.

  • Global Usage and Future Plans: The Hugo RAS system has been utilized in over 30 countries for various surgical procedures, with plans to expand its use in the U.S. to include general and gynecologic surgeries.

[object Object]
Preview
9.0
12-04SeekingAlpha
PinnedMedtronic Receives FDA Approval for Hugo Robotic-Assisted Surgery System

  • FDA Approval: Medtronic's Hugo robotic surgery system has received approval from the U.S. FDA for use in urologic surgeries.

  • Minimally Invasive Procedures: The Hugo RAS system is now authorized for minimally invasive urologic procedures, including prostatectomy, nephrectomy, and cystectomy.

[object Object]
Preview
8.0
06:13 AMNewsfilter
Medtronic Declares $0.71 Cash Dividend for Q3 FY2026
  • Dividend Growth: On December 4, 2025, Medtronic's board approved a cash dividend of $0.71 per share for Q3 FY2026, consistent with the increase announced in May 2025, reflecting the company's ongoing profitability and commitment to shareholder returns.
  • Historical Achievement: Medtronic has increased its annual dividend for 48 consecutive years, making it a constituent of the S&P 500 Dividend Aristocrats index, which underscores its leadership in the healthcare technology sector and stable financial performance.
  • Payment Schedule: The dividend will be payable on January 16, 2026, to shareholders of record as of December 26, 2025, ensuring timely returns for investors and further boosting investor confidence.
  • Strategic Implications: By maintaining consistent dividend growth, Medtronic not only attracts more long-term investors but also enhances its appeal in the competitive healthcare technology market, supporting future innovation and development.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Medtronic PLC (MDT) stock price today?

The current price of MDT is 101.99 USD — it has increased 0.02 % in the last trading day.

arrow icon

What is Medtronic PLC (MDT)'s business?

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

arrow icon

What is the price predicton of MDT Stock?

Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Medtronic PLC (MDT)'s revenue for the last quarter?

Medtronic PLC revenue for the last quarter amounts to 8.96B USD, increased 6.64 % YoY.

arrow icon

What is Medtronic PLC (MDT)'s earnings per share (EPS) for the last quarter?

Medtronic PLC. EPS for the last quarter amounts to 1.07 USD, increased 8.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for Medtronic PLC (MDT)'s fundamentals?

The market is revising Upward the revenue expectations for Medtronic plc (MDT) for FY2026, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by 9.84%.
arrow icon

How many employees does Medtronic PLC (MDT). have?

Medtronic PLC (MDT) has 95000 emplpoyees as of December 05 2025.

arrow icon

What is Medtronic PLC (MDT) market cap?

Today MDT has the market capitalization of 130.75B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free